BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 23581433)

  • 21. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
    Sokolowska-Wojdylo M; Florek A; Zaucha JM; Chmielowska E; Giza A; Knopinska-Posluszny W; Kulikowski W; Prejzner W; Romejko-Jarosinska J; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Rogowski W; Grzanka A; Placek W; Lugowska-Umer H; Kowalczyk A; Nowicki R; Jurczak W
    Am J Ther; 2016; 23(3):e749-56. PubMed ID: 24732904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sézary syndrome in an 11-year-old girl.
    Meister L; Duarte AM; Davis J; Perez JL; Schachner LA
    J Am Acad Dermatol; 1993 Jan; 28(1):93-5. PubMed ID: 8425978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
    Stern DK; Lebwohl M
    J Drugs Dermatol; 2002 Sep; 1(2):134-6. PubMed ID: 12847736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New and established treatment options for mycosis fungoides and Sézary syndrome - an update.
    Dugas-Breit S; Schulze HJ; Hallermann C
    J Dtsch Dermatol Ges; 2014 Jul; 12(7):561-9. PubMed ID: 24889480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bexarotene plus PUVA plus radiation combination therapy for mycosis fungoides.
    Coors E
    Dermatol Clin; 2008 Jan; 26 Suppl 1():33-5. PubMed ID: 18405185
    [No Abstract]   [Full Text] [Related]  

  • 26. The use of amitriptyline in mycosis fungoides.
    Coe P
    Palliat Med; 1999 May; 13(3):264. PubMed ID: 10474718
    [No Abstract]   [Full Text] [Related]  

  • 27. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial.
    Duvic M; Dummer R; Becker JC; Poulalhon N; Ortiz Romero P; Grazia Bernengo M; Lebbé C; Assaf C; Squier M; Williams D; Marshood M; Tai F; Prince HM
    Eur J Cancer; 2013 Jan; 49(2):386-94. PubMed ID: 22981498
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 13-cis-retinoic acid effective in mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group.
    Thomsen K; Molin L; Volden G; Lange Wantzin G; Hellbe L
    Acta Derm Venereol; 1984; 64(6):563-6. PubMed ID: 6084938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination chemotherapy with bleomycin, cyclophosphamide, prednisone and etretinate (BCPE) in advanced mycosis fungoides: a six-year experience.
    Zachariae H; Thestrup-Pedersen K
    Acta Derm Venereol; 1987; 67(5):433-7. PubMed ID: 2448996
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disappearance of seborrheic keratoses following treatment with methotrexate.
    Seyfer SJ; Duvic M
    Cutis; 2013 Jul; 92(1):E2-3. PubMed ID: 23961531
    [No Abstract]   [Full Text] [Related]  

  • 31. Mycosis fungoides/Sézary syndrome: a report of three cases treated with Campath-1H as salvage treatment.
    Capalbo S; Delia M; Dargenio M; Liso A; Diomede D; Garofalo L; Liso V
    Med Oncol; 2003; 20(4):389-96. PubMed ID: 14716037
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mycosis fungoides and the Sézary syndrome.
    Foss F
    Curr Opin Oncol; 2004 Sep; 16(5):421-8. PubMed ID: 15314509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of multiple basal cell carcinomas in mycosis fungoides treated with oral bexarotene.
    Calzavara-Pinton P; Leali C; Venturini M; Sala R; Zane C
    Eur J Dermatol; 2007; 17(4):341-2. PubMed ID: 17540649
    [No Abstract]   [Full Text] [Related]  

  • 34. Mycosis fungoides bullosa.
    Natsuga K; Shimizu T; Abe R; Kodama K; Shimizu H
    Arch Dermatol; 2006 Jun; 142(6):793-5. PubMed ID: 16785397
    [No Abstract]   [Full Text] [Related]  

  • 35. Systematic review of combination therapies for mycosis fungoides.
    Humme D; Nast A; Erdmann R; Vandersee S; Beyer M
    Cancer Treat Rev; 2014 Sep; 40(8):927-33. PubMed ID: 24997678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the efficacy of the combination of oral bexarotene and methotrexate for the treatment of early stage treatment-refractory cutaneous T-cell lymphoma.
    Kannangara AP; Levitan D; Fleischer AB
    J Dermatolog Treat; 2009; 20(3):169-76. PubMed ID: 19016373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of bexarotene combined with psoralen-ultraviolet A (PUVA) compared with PUVA treatment alone in stage IB-IIA mycosis fungoides: final results from the EORTC Cutaneous Lymphoma Task Force phase III randomized clinical trial (NCT00056056).
    Whittaker S; Ortiz P; Dummer R; Ranki A; Hasan B; Meulemans B; Gellrich S; Knobler R; Stadler R; Karrasch M
    Br J Dermatol; 2012 Sep; 167(3):678-87. PubMed ID: 22924950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of mycosis fungoides with bexarotene and psoralen plus ultraviolet A.
    Coors EA; Von den Driesch P
    Br J Dermatol; 2005 Jun; 152(6):1379-81. PubMed ID: 15949024
    [No Abstract]   [Full Text] [Related]  

  • 39. Cutaneous T-cell lymphoma's confounding nature.
    Schmidt C
    J Natl Cancer Inst; 2012 Jun; 104(11):806-8. PubMed ID: 22673589
    [No Abstract]   [Full Text] [Related]  

  • 40. A trial of fludarabine and cyclophosphamide combination chemotherapy in the treatment of advanced refractory primary cutaneous T-cell lymphoma.
    Scarisbrick JJ; Child FJ; Clift A; Sabroe R; Whittaker SJ; Spittle M; Russell-Jones R
    Br J Dermatol; 2001 May; 144(5):1010-5. PubMed ID: 11359390
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.